Anifrolumab-fnia (Saphnelo)
The FDA approved Anifrolumab in 2021 for the treatment of adult patients with moderate or severe systemic lupus erythematosus. Anifrolumab may be used in combination with other drugs, such as hydroxychloroquine and glucocorticoids (steroids).
